Prosecution Insights
Last updated: November 04, 2026
Application No. 18/688,983

FUNGAL ENZYME MIXTURES AND USES THEREOF

Final Rejection §103
Filed
Mar 04, 2024
Priority
Sep 02, 2021 — provisional 63/240,255 +1 more
Examiner
JONES-FOSTER, ERICA NICOLE
Art Unit
1656
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Bio-Cat Inc.
OA Round
2 (Final)
50%
Grant Probability
Moderate
3-4
OA Rounds
10m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allowance Rate
44 granted / 88 resolved
-10.0% vs TC avg
Strong +38% interview lift
Without
With
+38.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
63 currently pending
Career history
160
Total Applications
across all art units

Statute-Specific Performance

§101
8.3%
-31.7% vs TC avg
§103
37.7%
-2.3% vs TC avg
§102
20.3%
-19.7% vs TC avg
§112
24.9%
-15.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 88 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Support for the amendments are within the instant application specification. Applicant’s amendment to the claims filed on 8/20/2026 in response to the Non-Final Rejection mailed on 2/20/2026 is acknowledged. This listing of claims replaces all prior listings of claims in the application. Claims 1-3, 5-6, 9, 12-14 are pending and examined on the merits. Claims 4, 7-8, 10-11, 16-19, 23-24, 26, 29 are canceled. Claims 15, 20-22, 25, 27-28 stands withdrawn pursuant to 37 CFR 1.142(b). Applicant’s remarks filed on 8/20/2026 in response to the Non-Final Rejection mailed on 2/20/2026 have been fully considered and are deemed persuasive to overcome at least one of the rejections and/or objections as previously applied. The text of those sections of Title 35 U.S. Code not included in the instant action can be found in the prior Office Action. Withdrawn Rejections The rejection of claims 1-3, 5-10, 12-13 under 35 U.S.C. 101 are withdrawn in view of Applicant’s cancellation of claims 7-8 and amendment of claim 1 to recite ‘wherein the enzyme mixture is in a dehydrated, powdered, granular, spray-dried or freeze-dried form.’ The rejection of claims 7-8, 10-11 under 35 U.S.C. 103 as being unpatentable over Schuler et al (US 8,071,089 B2, Date of Patent: Dec. 6, 2011, cited in PTO-892 dated 2-20-2026) {herein Schuler} in view of Gregory et al (WO 2019060851 A1, Date of Publication: 28 March 2019, cited in PTO-892 dated 2-20-2026) {herein Gregory} is withdrawn in view of Applicant’s cancellation of claims 7-8, 10-11. Maintained Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The rejection of claims 1-3, 5, 9, 12-14 under 35 U.S.C. 103 as being unpatentable over Schuler et al (US 8,071,089 B2, Date of Patent: Dec. 6, 2011, Examiner cited) {herein Schuler} in view of Gregory et al (WO 2019060851 A1, Date of Publication: 28 March 2019, Examiner cited) {herein Gregory} are . Claims 1-3, 5, 9, 12-14 are drawn to an enzyme mixture comprising a plurality of fungal enzymes from members of the genus Aspergillus and Candida, wherein the plurality of fungal enzymes comprises: (a) a protease obtained from A. oryzae, (b) a protease obtained from A. niger, (c) a protease obtained from A. melleus, (d) a lipase obtained from C. rylindracea or a lipase obtained from R. oryzae, (e) an amylase obtained from A. oryzae, and (f) a glucoamylase obtained from A. niger, wherein the enzyme mixture has exopeptidase, endopeptidase, lipase, alpha-amylase, and glucoamylase activities, wherein the enzyme mixture comprises amino acid sequences which share at least 90% full-length sequence identity with SEQ ID NOs: 1-2 and 4-7, and wherein the enzyme mixture is in a dehydrated, powdered, granular, spray-dried or freeze-dried form. With respect to claims 1, 12- 14, Schuler teaches an enzyme mixture comprising a plurality of fungal enzymes from members of the genus Aspergillus and Candida (column 2, lines 45-47). Said fungal enzymes are: Aspergillus niger protease (column 2, lines 53-54), Aspergillus melleus protease (column 2, line 19), Aspergillus oryzae amylase (column 2, lines 20), Candida cylindracea lipase (column 2, lines 46-47), Aspergillus niger amyloglucosidase (same as glucoamylase) (column 2, lines 54-55). The instant application recites SEQ ID Nos: 5-7 which are SEQ ID NO: 5 Candida cylindracea lipase 1 (column 10, line 16), SEQ ID NO: 6 which is A. niger G1 glucoamylase (same as amyloglucosidase) (column 9, lines 35), SEQ ID NO: 7 which is Aspergillus melleus alkaline protease 1 (column 2, lines 19-20) Therefore, it is the Examiner’s position that said fungal enzymes would necessarily have “at least 90% sequence identity” to the full-length recited SEQ ID Nos: 5-7 which are SEQ ID NO: 5 Candida cylindracea lipase 1 (column 10, line 16), SEQ ID NO: 6 which is A. niger G1 glucoamylase (same as amyloglucosidase) (column 9, lines 35), SEQ ID NO: 7 which is Aspergillus melleus alkaline protease 1 (column 2, lines 19-20). Additionally, since Schuler teaches the structure of an enzyme mixture comprising a plurality of fungal enzymes from members of the genus Aspergillus and Candida, absent evidence otherwise, it is the Examiner’s position that said composition would necessarily comprise exopeptidase, endopeptidase, lipase, alpha-amylase, and glucoamylase activities. Schuler further teaches said composition is an improved supplement to aid in digestion (column 2, lines 35-37). It is the Examiner’s position that said composition is a dietary supplement as it improves digestive health in patients with cystic fibrosis (column 2, lines 35-37). In addition, said composition is in capsule or tablet form (column 9, line 22). Therefore, said composition is granular, dehydrated and powder (column 8, line 18). With respect to claims 6-9, 10, Schuler teaches an enzyme composition comprised of Candida cylindracea lipase 1 (Schuler column 10, line 16), a protease from Aspergillus melleus (column 2, lines 19) and A. niger G1 glucoamylase (same as amyloglucosidase) (Schuler column 9, lines 35). It is the Examiner position that said enzymes have at least 90% full-length sequence identity to SEQ ID NO: 5 - Candida cylindracea lipase 1 (Schuler column 10, line 16), SEQ ID NO: 7 - a protease from Aspergillus melleus and SEQ ID NO: 6 - A. niger G1 glucoamylase (same as amyloglucosidase) (Schuler column 9, lines 35) since said recited sequences are not modified. However, Schuler does not teach a protease obtained from Aspergillus oryzae (claim 1). Schuler does not teach the enzyme concentrations of claims 2 and 3. Schuler does not teach the enzyme mixture of claim 1, wherein the ratio of the 3 fungal proteases : lipase : amylase : glucoamylase is: a) 3600: 120 : 400: 1; or b) 1800-5400 : 30-180 : 200-600 : 0.5-1.5; as measured in hemoglobin unit tyrosine base units (HUT): Federation Internationale Pharmaceutique units (FIP): Sandstedt, Kneen, and Blish method units (SKB): Amyloglucosidase units (AGU) (claim 5). Schulaer does not teach wherein the enzyme mixture comprises at least four, five, six, or seven of SEQ ID NOs: 1, 2, 4 (claim 6). Schuler does not teach wherein the enzyme mixture comprises SEQ ID NOs: 1, 2, and 4 (claim 9). With respect to claims 1, 9, Gregory teaches a fungal protease composition comprised of mixtures of Aspergillus proteases (abstract). Said composition is comprised of fungal protease from A. oryzae (para 0084), amylase from A. oryzae (para 0084). Furthermore, said composition comprises Aspergillopepsin-1, an aspartic endopeptidase produced by A. oryzae (para 0087). Said composition has endopeptidase (para 0087) and alpha-amylase activities (para 0098). It is the Examiner’s position that said fungal enzymes would necessarily have “at least 90% sequence identity” to the full-length recited SEQ ID NOs: 1-2, 4 as Gregory teaches SEQ ID NO: 1- an Aspergillus oryzae protease sequence (para 0084), SEQ ID NO: 2 - A. niger aspergillopepsin I polypeptide (para 0087), SEQ ID NO: 4 - Aspergillus oryzae alpha amylase (para 0084) as the instant application does not teaches said sequences are modified and Gregory teaches unmodified sequences of the claimed composition. Since the instant application has no recitation of said sequences being modified, it is the Examiner’s position that it would be obvious to one of ordinary skill in the art that Gregory teaches the enzyme mixture comprises amino acid sequences which share at least 90% full-length sequence identity with SEQ ID NOs: 1-2, 4, as recited in the instant application claim 1. Therefore, the above invention would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention. With respect to claims 2-3, Gregory teaches the amounts or ratios of enzymes may be varied to produce a mixture having enhanced or reduced activity levels (para 0086). Although the references of Schuler in view of Gregory do not explicitly teach the limitations of claims 2-3 (fungal enzyme concentrations), MPEP 2144.05 states"[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (MPEP 2144.05 IIA)." One of ordinary skill would desire to optimize the fungal enzyme concentrations depending on the particular application. It would be routine for one to arrive at the fungal enzyme concentrations for the application they intend on using the enzyme mixture. Therefore, the above invention would have been prima facie obvious. With respect to claim 5, although the references of Schuler in view of Gregory do not explicitly teach the limitations of claim 5 (ratio of fungal proteases), MPEP 2144.05 states"[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (MPEP 2144.05 IIA)." One of ordinary skill would desire to optimize the fungal proteases ratios depending on the particular application. It would be routine for one to arrive at the fungal protease ratios for the application they intend on using the enzyme mixture. Therefore, the above invention would have been prima facie obvious. Before the effective filing date of the claimed invention, it would have been obvious to one of ordinary skill in the art to apply the teachings of Schuler et al of an enzyme mixture comprising a plurality of fungal enzymes from members of the genus Aspergillus and Candida (column 2, lines 45-47) or combine the teachings of Gregory et al of a fungal protease composition comprised of mixtures of Aspergillus proteases (abstract). One of ordinary skill in the art would be motivated to either use the teachings of Schuler et al. by itself or combine the teachings of Gregory because Gregory provides the motivation for Schuler to add a protease obtained from A. oryzae because Gregory teaches said protease produces a protein hydrolysate enriched in essential amino acids and/or branched chain amino acids, and may also possess additional beneficial properties (para 0077). One of ordinary skill in the art knowing the benefit of fungal enzymes based on the teachings of Schuler and Gregory would have a reasonable expectation of success to combine A. oryzae protease, taught by Gregory, with the fungal enzyme composition taught by Schuler as Gregory teaches A. oryzae protease can be added to dietary supplements containing other fungal proteases without the need for supplementation with additional essential amino acids or branched chain amino acids from another source (Gregory: para 0077) of which is one of the goals of Schuler (Schuler: column 5, lines 63-67; column 6, lines 1-3). One of skill in the art would have a reasonable expectation of success to make and use the claimed fungal enzyme composition because Schuler provides the basic fungal enzyme composition and its uses and methods of making it. Reference of Gregory provides the teachings of a fungal protease composition comprised of mixtures of Aspergillus proteases (abstract). Therefore there would be a reasonable expectation of success to arrive at the above invention. Therefore, the above invention would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention. RESPONSE TO REMARKS: Beginning on p. 6 of Applicant’s remarks, Applicant in summary contends that there is no reason to combine the references since they relate to distinct compositions that address different needs. The argument is not persuasive. Examiner contends that Gregory provides the motivation for Schuler to add a protease obtained from A. oryzae because Gregory teaches said protease produces a protein hydrolysate enriched in essential amino acids (para 0077), therefore one of ordinary skill in the art knowing the benefit of fungal enzymes based on the teachings of Schuler and Gregory would have a reasonable expectation of success to combine A. oryzae protease, taught by Gregory, with the fungal enzyme composition taught by Schuler as Gregory teaches A. oryzae protease can be added to dietary supplements without supplementation with additional essential amino acids (para 0077), thereby providing complementary activity profiles across the entire digestive tract. Applicant contends that the specification discloses unexpected results. See, e.g., Example 2. The argument is not persuasive. Examiner contends that Applicant’s reported ‘unexpected results’ of a superior performance of the claimed enzyme mixture on glycerol release and triglyceride reduction, based on Applicant’s Example 2 in the instant application specification, is not part of the instant application claim language. Additionally, Examiner contends that since Schuler in view of Gregory teach the structure of an enzyme mixture comprising a plurality of fungal enzymes from members of the genus Aspergillus and Candida, then said composition would necessarily result in having a superior performance on glycerol release and triglyceride reduction. Furthermore, Applicant is reminded that the instant claims are read in-light of the specification. MPEP 2111 states “During patent examination, the pending claims must be "given their broadest reasonable interpretation consistent with the specification." The Federal Circuit’s en banc decision in Phillips v. AWH Corp., 415 F.3d 1303, 1316, 75 USPQ2d 1321, 1329 (Fed. Cir. 2005) expressly recognized that the USPTO employs the "broadest reasonable interpretation" standard: The Patent and Trademark Office ("PTO") determines the scope of claims in patent applications not solely on the basis of the claim language, but upon giving claims their broadest reasonable construction "in light of the specification as it would be interpreted by one of ordinary skill in the art." In re Am. Acad. of Sci. Tech. Ctr., 367 F.3d 1359, 1364[, 70 USPQ2d 1827, 1830] (Fed. Cir. 2004). Indeed, the rules of the PTO require that application claims must "conform to the invention as set forth in the remainder of the specification and the terms and phrases used in the claims must find clear support or antecedent basis in the description so that the meaning of the terms in the claims may be ascertainable by reference to the description." 37 CFR 1.75(d)(1).” In addition, Examiner contends that Gregory provides Schuler the motivation to add A. oryzae protease to the composition comprising Candida cylindracea lipase 1, a protease from Aspergillus melleus and A. niger G1 glucoamylase (same as amyloglucosidase) as Gregory teaches A. oryzae protease can be added to dietary supplements without the need for supplementation with additional essential amino acids or branched chain amino acids from another source (para 0077) of which is one of the goals of Schuler with the teaching of ‘providing multiple proteases with different specificities facilitates more complete breakdown of proteins and peptides into amino acids in the digestive process’ (column 5, lines 63-67; column 6, lines 1-3). Thereby, said composition would provide complementary activity profiles across the entire digestive tract without the need for any additional sources of amino acids. Conclusion Status of Claims Claims 1-3, 5-6, 9, 12-14 are pending and examined on the merits. Claims 4, 7-8, 10-11, 16-19, 23-24, 26, 29 are canceled. Claims 15, 20-22, 25, 27-28 stands withdrawn pursuant to 37 CFR 1.142(b). Claims 1-3, 5-6, 9, 12-14 are rejected. No claims are in condition for allowance. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERICA NICOLE JONES-FOSTER whose telephone number is (571)270-0360. The examiner can normally be reached mf 7:30a - 4:30p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Manjunath Rao can be reached at 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ERICA NICOLE JONES-FOSTER/ Examiner, Art Unit 1656 /MANJUNATH N RAO/ Supervisory Patent Examiner, Art Unit 1656
Read full office action

Prosecution Timeline

Mar 04, 2024
Application Filed
Feb 20, 2026
Non-Final Rejection mailed — §103
Aug 20, 2026
Response Filed
Oct 30, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781203
ATP-INDEPENDENT BIOLUMINESCENT REPORTER VARIANTS TO IMPROVE IN VIVO IMAGING
5y 2m to grant Granted Nov 03, 2026
Patent 12643927
ENGINEERED SPIDER SILK PROTEINS AND USES THEREOF
3y 9m to grant Granted Jun 02, 2026
Patent 12600761
METHODS AND COMPOSITIONS FOR PURIFICATION OF TRIMERIC FUSION PROTEINS
3y 1m to grant Granted Apr 14, 2026
Patent 12594308
METHODS OF PREPARING A POSTBIOTIC COMPOSITION
1y 6m to grant Granted Apr 07, 2026
Patent 12590291
METHOD OF INDUCING EXPRESSION OF CALCIUM CHANNEL AND/OR CALCIUM PUMP, AND APPARATUS THEREFOR
3y 11m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
50%
Grant Probability
88%
With Interview (+38.0%)
3y 6m (~10m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 88 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month